Financhill
Back

Rapport Therapeutics, Inc. Stock Price Chart

This Tech Company Grew 32,481%...

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
26

RAPP
Rapport Therapeutics, Inc.

Last Price:
$30.17
Seasonality Move:
-47.31%

7 Day Trial

ALL ACCESS PASS

$ 7
  • Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and RAPP is experiencing slight buying pressure.

Rapport Therapeutics, Inc. Price Chart Indicators

Moving Averages Level Buy or Sell
8-day SMA: 30.45 Sell
20-day SMA: 29.55 Buy
50-day SMA: 27.66 Buy
200-day SMA: 18.05 Buy
8-day EMA: 25.3 Buy
20-day EMA: 15.36 Buy
50-day EMA: 7.43 Buy
200-day EMA: 2.06 Buy

Rapport Therapeutics, Inc. Technical Analysis Indicators

Chart Indicators Level Buy or Sell
MACD (12, 26): 8.36 Buy
Relative Strength Index (14 RSI): 54.61 Buy
Chaikin Money Flow: 84937 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (28 - 30.52) Buy
Bollinger Bands (100): (19.27 - 29.97) Buy

Rapport Therapeutics, Inc. Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):

Technical Analysis for Rapport Therapeutics, Inc. Stock

Is Rapport Therapeutics, Inc. Stock a Buy?

RAPP Technical Analysis vs Fundamental Analysis

Sell
26
Rapport Therapeutics, Inc. (RAPP) is a Sell

Is Rapport Therapeutics, Inc. a Buy or a Sell?

Rapport Therapeutics, Inc. Stock Info

Market Cap:
1.1B
Price in USD:
30.20
Share Volume:
221.9K

Rapport Therapeutics, Inc. 52-Week Range

52-Week High:
42.27
52-Week Low:
6.43
Sell
26
Rapport Therapeutics, Inc. (RAPP) is a Sell

Rapport Therapeutics, Inc. Share Price Forecast

Is Rapport Therapeutics, Inc. Stock a Buy?

Fundamental Analysis of Rapport Therapeutics, Inc.

Is Rapport Therapeutics, Inc. a good investment?

  • Analysts estimate an earnings increase this quarter of $0.19 per share, a decrease next quarter of $0.00 per share, an increase this year of $11.14 per share, and a decrease next year of $0.61 per share.

Technical Analysis of Rapport Therapeutics, Inc.

Should I short Rapport Therapeutics, Inc. stock?

* Rapport Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.